Zobrazeno 1 - 10
of 300
pro vyhledávání: '"Indolent Non-Hodgkin Lymphoma"'
Autor:
Olalekan O. Oluwole, Markqayne D. Ray, Richard M. Zur, Cheryl P. Ferrufino, Brett Doble, Anik R. Patel, S. Pinar Bilir
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionNovel therapies for 3L+ relapsed/refractory (r/r) follicular lymphoma (FL) have been approved recently by the US Food and Drug Administration including anti-CD19 CAR-T therapies such as axicabtagene ciloleucel (axi-cel) and CD20 × CD3 T-
Externí odkaz:
https://doaj.org/article/0bf9658a2eb640f7b7c7528ac49a045b
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 13, Pp 201-211 (2021)
Elizabeth James,1 Holly Trautman,1 Stephen Thompson,2 Rinat Ribalov,3 Azhar Choudhry4 1Aventine Consulting LLC, Marblehead, MA, USA; 2Global Health Economics and Outcomes Research, Teva Branded Pharmaceutical Products R&D, Inc, Parsippany, NJ, USA; 3
Externí odkaz:
https://doaj.org/article/c6f6ab3bf64846df96cf0d1c67304574
Publikováno v:
Drugs in Context, Vol 9, Pp 1-12 (2020)
The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the ear
Externí odkaz:
https://doaj.org/article/2cbfc9397c794be4951defc1684b1475
Publikováno v:
Leukemia Research Reports, Vol 16, Iss , Pp 100275- (2021)
Monoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases. Rituximab, a chimeric anti-CD20 mAb, was the
Externí odkaz:
https://doaj.org/article/4ff297b9765e4eb0873c0119a47368c5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Drugs in Context, Vol 9, Pp 1-12 (2020)
Drugs in Context
Drugs in Context
The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the ear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84ee12f6ce164208ab2229240529868
https://drugsincontext.com/use-of-anti-cd20-therapy-in-follicular-and-marginal-zone-lymphoma:-a-review-of-the-literature
https://drugsincontext.com/use-of-anti-cd20-therapy-in-follicular-and-marginal-zone-lymphoma:-a-review-of-the-literature
Autor:
Yuan-Kai Shi, Xiao-Nan Hong, Jian-Liang Yang, Wei Xu, Hui-Qiang Huang, Xiu-Bin Xiao, Jun Zhu, Dao-Bin Zhou, Xiao-Hong Han, Jian-Qiu Wu, Ming-Zhi Zhang, Jie Jin, Xiao-Yan Ke, Wei Li, De-Pei Wu, Shen-Miao Yang, Xin Du, Yong-Qian Jia, Ai-Chun Liu, Dai-Hong Liu, Zhi-Xiang Shen, Lian-Sheng Zhang, Leonard James, Edward Hellriegel, Peng Lyu
Publikováno v:
Chinese Medical Journal, Vol 134, Iss 11, Pp 1299-1309 (2021)
Chinese Medical Journal
Chinese Medical Journal
Background:. Bendamustine was approved in China on May 26th, 2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL). The current study was the registration trial and the first reported eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17be65cfe45db2d4ab04a5c9a67c2f2c
http://journals.lww.com/10.1097/CM9.0000000000001463
http://journals.lww.com/10.1097/CM9.0000000000001463
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Elizabeth James,1 Holly Trautman,1 Stephen Thompson,2 Rinat Ribalov,3 Azhar Choudhry4 1Aventine Consulting LLC, Marblehead, MA, USA; 2Global Health Economics and Outcomes Research, Teva Branded Pharmaceutical Products R&D, Inc, Parsippany, NJ, USA; 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b860093a77c20f03db07f2ee50a16203
https://doi.org/10.2147/ceor.s297284
https://doi.org/10.2147/ceor.s297284
Autor:
Simon Rule, Sonja Nick, Chris Pocock, Javier Briones, Clemens-Martin Wendtner, Lachlan MacGregor, Roger R Tschopp, Susan Robson, Martin Dreyling, Olivier Casasnovas, Angelo Michele Carella, Francesco Zaja, Wolney Barreto
Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 years confers a long-term benefit in terms of progression-free survival in patients with indolent non-Hodgkin lymphoma. It is not known whether further prolonged main
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509e32dfce4c90ab03380f13c259964f
https://hdl.handle.net/11368/3029195
https://hdl.handle.net/11368/3029195
Autor:
Vicky Jones, Andres Forero-Torres, Leonard M. Klein, Christopher A. Yasenchak, David Andorsky, Jeff P. Sharman, Kathryn S. Kolibaba, Sarit Assouline, Mitchell R. Smith, Wei Ye, Dipti Patel-Donnelly, Wen Shi
Publikováno v:
British Journal of Haematology
Summary Spleen tyrosine kinase (Syk) mediates B‐cell receptor signalling in normal and malignant B cells. Entospletinib is an oral, selective Syk inhibitor. Entospletinib monotherapy was evaluated in a multicentre, phase 2 study of patients with re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3376a4d1a085af2b701021947094d4
http://europepmc.org/articles/PMC6585960
http://europepmc.org/articles/PMC6585960